Adverse effects associated with the use of FK 506.
作者信息
Fung J J, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Van Thiel D, Armitage J, Jain A, McCauley J
机构信息
Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania.
出版信息
Transplant Proc. 1991 Dec;23(6):3105-8.
Abstract
摘要
相似文献
1
Adverse effects associated with the use of FK 506.与使用FK 506相关的不良反应。
Transplant Proc. 1991 Dec;23(6):3105-8.
2
Neurologic complications of FK 506.FK506的神经并发症
Transplant Proc. 1991 Dec;23(6):3175-8.
3
Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression.在FK 506免疫抑制下肾移植后非裔美国人的移植后糖尿病
Transplant Proc. 1993 Aug;25(4):2433-4.
4
Adverse effects of FK 506 overdosage after liver transplantation.肝移植后FK 506过量的不良反应。
Transplant Proc. 1993 Feb;25(1 Pt 1):628-34.
5
Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity.肝移植后每日三次给予他克莫司（FK 506）以将肾毒性和神经毒性降至最低。
Transplant Proc. 2003 Nov;35(7):2787-8. doi: 10.1016/j.transproceed.2003.09.009.
6
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.他克莫司在胰腺移植中的应用：一项多中心分析。他克莫司胰腺移植研究组。
Clin Transplant. 1997 Aug;11(4):299-312.
7
Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506.肝移植中的神经病理学发现：环孢素与FK506的比较研究
Transplant Proc. 1991 Dec;23(6):3181-2.
8
Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression.
Transplant Proc. 1996 Jun;28(3):1304-5.
9
Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients.原位肝移植患者从环孢素A转换为他克莫司（FK 506）后生活质量的变化。
Transplant Proc. 1991 Dec;23(6):3032-4.
10
Long-term insulin requirement after liver transplantation with FK 506 in American veterans.美国退伍军人肝移植后使用FK 506的长期胰岛素需求情况。
Transplant Proc. 1993 Feb;25(1 Pt 1):677-8.
引用本文的文献
1
Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.抑制钙调神经磷酸酶可能预防唐氏综合征患者患阿尔茨海默病。
Alzheimers Dement. 2025 Mar;21(3):e70034. doi: 10.1002/alz.70034.
2
The role of the FKBP51-Hsp90 complex in Alzheimer's disease: An emerging new drug target.FKBP51-Hsp90复合物在阿尔茨海默病中的作用：一个新出现的药物靶点。
Cell Stress Chaperones. 2024 Dec;29(6):792-804. doi: 10.1016/j.cstres.2024.11.006. Epub 2024 Nov 29.
3
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.重复给予利妥昔单抗可使 MCD 或 FSGS 患者达到并维持临床缓解。
Sci Rep. 2023 Apr 28;13(1):6980. doi: 10.1038/s41598-023-32576-7.
4
Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.设计生物材料以调节 1 型糖尿病中细胞移植物的同种异体和自身免疫反应。
Acta Biomater. 2021 Oct 1;133:87-101. doi: 10.1016/j.actbio.2021.05.039. Epub 2021 Jun 5.
5
Isoform-Selective NFAT Inhibitor: Potential Usefulness and Development.同种型选择性 NFAT 抑制剂：潜在的用处和研发进展。
Int J Mol Sci. 2021 Mar 8;22(5):2725. doi: 10.3390/ijms22052725.
6
Safety and effectiveness of mycophenolate mofetil associated with tacrolimus for liver transplantation immunosuppression: a systematic review and meta-analysis of randomized controlled trials.霉酚酸酯联合他克莫司用于肝移植免疫抑制的安全性和有效性：系统评价和随机对照试验的荟萃分析。
Clinics (Sao Paulo). 2021 Mar 8;76:e2597. doi: 10.6061/clinics/2021/e2597. eCollection 2021.
7
New-onset Psychosis in an Immunosuppressed Patient With Kidney Transplantation: An Educational Case Report.一名肾移植免疫抑制患者的新发精神病：一份教育性病例报告。
Can J Kidney Health Dis. 2020 Aug 4;7:2054358120947210. doi: 10.1177/2054358120947210. eCollection 2020.
8
Melibiosamine, a novel oligosaccharide, suppresses mitogen-induced IL-2 production via inactivation of NFAT and NFκB in Jurkat cells.蜜二糖胺，一种新型寡糖，通过使Jurkat细胞中的NFAT和NFκB失活来抑制丝裂原诱导的IL-2产生。
Biochem Biophys Rep. 2019 Jun 14;19:100658. doi: 10.1016/j.bbrep.2019.100658. eCollection 2019 Sep.
9
Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review.移植后后部可逆性脑病综合征：综述
Mol Neurobiol. 2016 Dec;53(10):6897-6909. doi: 10.1007/s12035-015-9560-0. Epub 2015 Dec 14.
10
Clausmarin A, Potential Immunosuppressant Revealed by Yeast-Based Assay and Interleukin-2 Production Assay in Jurkat T Cells.克劳斯马林A，一种通过酵母检测法和人急性T淋巴细胞白血病细胞系（Jurkat T细胞）白细胞介素-2产生检测法揭示的潜在免疫抑制剂。
PLoS One. 2015 Aug 27;10(8):e0136804. doi: 10.1371/journal.pone.0136804. eCollection 2015.
本文引用的文献
1
FK 506 in the management of nephrotic syndrome after renal transplantation.FK506在肾移植后肾病综合征管理中的应用
Transplant Proc. 1993 Feb;25(1 Pt 2):1351-4.
2
Liver transplantation with use of cyclosporin a and prednisone.使用环孢素A和泼尼松进行肝移植。
N Engl J Med. 1981 Jul 30;305(5):266-9. doi: 10.1056/NEJM198107303050507.
3
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients.环孢素A在肝肾移植患者中的肾毒性
Lancet. 1981 Feb 28;1(8218):470-1. doi: 10.1016/s0140-6736(81)91851-1.
4
Cancers following cyclosporine therapy.
Transplantation. 1987 Jan;43(1):32-5. doi: 10.1097/00007890-198701000-00008.
5
Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring.环孢素监测中的关键问题：环孢素监测特别工作组报告
Clin Chem. 1987 Jul;33(7):1269-88.
6
The diagnosis and treatment of posttransplant lymphoproliferative disorders.移植后淋巴细胞增生性疾病的诊断与治疗
Curr Probl Surg. 1988 Jun;25(6):367-472. doi: 10.1016/0011-3840(88)90011-1.
7
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
8
A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.免疫抑制剂FK506的一种受体是一种顺反肽基脯氨酰异构酶。
Nature. 1989 Oct 26;341(6244):758-60. doi: 10.1038/341758a0.
9
10
Zotero 插件